ArticleRespiratory medicine case reports2017
Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases.
Article in Respiratory medicine case reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports.Cancer immunology, immunotherapy : CII · 2021Pooled it
- Modern therapies of nonsmall cell lung cancer.Journal of applied genetics · 2023Review
- Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives.Molecular biology reports · 2023Review
- Advances in immune checkpoint inhibitors induced-cardiotoxicity.Frontiers in immunology · 2023Review
- Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab.Internal medicine (Tokyo, Japan) · 2021Article
- Review
- Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model.Journal for immunotherapy of cancer · 2020Article
- Chitinase 3 like 1 suppresses the stability and activity of p53 to promote lung tumorigenesis.Cell communication and signaling : CCS · 2020Article
- Inhaled chemotherapy adverse effects: mechanisms and protection methods.Lung cancer management · 2020Review
- Sex Differences and Adverse Effects between Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer.Journal of Cancer · 2020Article
- Acute pneumothorax due to immunotherapy administration in non-small cell lung cancer.Respiratory medicine case reports · 2020Article
- Pericardial effusion under nivolumab: case-reports and review of the literature.Journal for immunotherapy of cancer · 2019Review
- Biopsy and rebiopsy for non-small-cell lung cancer: current and future methods.Lung cancer management · 2019Article
- Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study.Journal of clinical medicine research · 2019Review
- Review
- Immunotherapy "Shock" a case series of PD-L1 100% and pembrolizumab first-line treatment.Respiratory medicine case reports · 2017Article
- Immunotherapy "Shock" with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma.Respiratory medicine case reports · 2017Article
- Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer.International journal of nanomedicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the past decade novel agents are on the market for non-small cell lung cancer adenocarcinoma based on pharmacogenomics. The epidermal growth factor receptor mutation, anaplastic lymphoma kinase and programmed death-ligand 1 investigation is necessary in the everyday clinical practice for the oncologic patient. Immunotherapy is nowadays the novel therapy for advanced stage non-small cell lung cancer with two agents nivolumab and pembrolizumab. In the current case series we will present adverse effects from our centers and comment on the treatment and follow-up of the patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.